What is HC Wainwright's Forecast for BBOT FY2026 Earnings?

Key Points

• HC Wainwright lowered its FY2026 EPS estimate for BridgeBio Oncology Therapeutics to ($2.12) from ($2.07) and maintained a Buy rating with a $29.00 price objective, also forecasting Q4 2026 EPS of ($0.55).
• The consensus full‑year EPS is ($2.18), and analyst coverage skews positive with three Buy ratings and one Sell, yielding a consensus target price of $26.00.
• BBOT recently traded around $8.46 (12‑month range $8.00–$14.87), has a market cap near $678M, and institutions own about 54.9% of the stock.

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT - Free Report) - HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of BridgeBio Oncology Therapeutics in a report issued on Friday, May 1st. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($2.12) per share for the year, down from their prior estimate of ($2.07). HC Wainwright currently has a "Buy" rating and a $29.00 price objective on the stock. The consensus estimate for BridgeBio Oncology Therapeutics' current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for BridgeBio Oncology Therapeutics' Q4 2026 earnings at ($0.55) EPS.

BBOT has been the topic of a number of other research reports. Weiss Ratings assumed coverage on BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They issued a "sell (d+)" rating on the stock. Stifel Nicolaus assumed coverage on BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a "buy" rating and a $23.00 target price on the stock. Finally, Raymond James Financial upgraded BridgeBio Oncology Therapeutics to a "moderate buy" rating in a research report on Friday, January 9th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, BridgeBio Oncology Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $26.00.

BridgeBio Oncology Therapeutics Price Performance

NASDAQ BBOT opened at $8.46 on Tuesday. The company has a 50-day moving average of $9.27. BridgeBio Oncology Therapeutics has a 12 month low of $8.00 and a 12 month high of $14.87. The company has a market cap of $677.73 million, a price-to-earnings ratio of -5.57 and a beta of 0.22.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. CIBC Private Wealth Group LLC bought a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $63,000. Persistent Asset Partners Ltd acquired a new position in BridgeBio Oncology Therapeutics during the 4th quarter worth approximately $107,000. Squarepoint Ops LLC acquired a new position in BridgeBio Oncology Therapeutics during the 4th quarter worth approximately $144,000. Quadrature Capital Ltd acquired a new position in BridgeBio Oncology Therapeutics during the 4th quarter worth approximately $162,000. Finally, BIT Capital GmbH acquired a new position in BridgeBio Oncology Therapeutics during the 4th quarter worth approximately $313,000. Institutional investors own 54.89% of the company's stock.

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics NASDAQ: BBOT is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.